Real-World Effectiveness of Xultophy® for Type 2 Diabetes Management in UAE

Many patients with Type 2 Diabetes (T2DM), a chronic metabolic condition characterized by high blood sugar, struggle to achieve optimal glycemic control with existing treatments like basal insulin or GLP-1 receptor agonists. While clinical trials demonstrate efficacy, there's a need to understand how these therapies perform in diverse populations and routine care. This study aimed to understand how the combination therapy Xultophy® performs in a real-world clinical setting in the United Arab Emirates when intensifying treatment for patients with inadequate control.

This study was a prospective non-interventional registration, and the provided abstract does not contain specific results or detailed data from the completed study. However, the primary objective was successfully met by collecting real-world information on how Xultophy® works in 300 patients with Type 2 Diabetes in the UAE. The study observed participants for approximately 26-34 weeks, gathering data on treatment patterns and clinical outcomes in a routine practice setting. > The core finding from this registration is the successful completion of a large-scale real-world study, which will provide valuable insights into the effectiveness and safety profile of Xultophy® when used for intensifying treatment in inadequately controlled Type 2 Diabetes. Specific quantitative results regarding glycemic control, body weight, and other parameters are expected to be disseminated in subsequent publications.